Filter
294
Filtered Results: 294
Text search:
FDC
Featured
Recommendations
45
New Publications
106
Language
Document type
No document type
218
Guidelines
27
Studies & Reports
23
Training Material
10
Manuals
6
Fact sheets
5
Strategic & Response Plan
3
Situation Updates
1
Resource Platforms
1
Countries / Regions
India
25
Tanzania
13
Kenya
11
South Africa
11
Namibia
11
Malawi
8
Zambia
6
Indonesia
6
Nepal
5
Ghana
5
Burkina Faso
5
Bangladesh
5
Uganda
5
Nigeria
4
Zimbabwe
4
Mozambique
4
Global
4
Cambodia
4
Ethiopia
4
Philippines
3
Liberia
3
Sierra Leone
2
Latin America and the Carribbean
2
Congo, Democratic Republic of
2
South–East Asia Region
2
Botswana
2
Myanmar / Burma
2
Eswatini/ Swaziland
2
Tajikistan
1
Timor Leste/ East Timor
1
Ukraine
1
Lesotho
1
Gambia
1
Rwanda
1
Cameroon
1
Albania
1
Senegal
1
Afghanistan
1
Haiti
1
Western and Central Europe
1
Paraguay
1
Gabon
1
France
1
Sri Lanka
1
Libya
1
Bhutan
1
Madagascar
1
Pakistan
1
Authors & Publishers
Publication Years
Category
Countries
150
Clinical Guidelines
41
Capacity Building
8
Public Health
7
Pharmacy & Technologies
7
Women & Child Health
3
Key Resources
3
Toolboxes
TB
70
HIV
48
AMR
18
Pharmacy
12
NTDs
5
Polio
4
Caregiver
3
NCDs
3
Refugee
2
COVID-19
2
Specific Hazards
1
Malaria
1
Global Health Education
1
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
This resource consists of technical guidelines for District Medical Officers, counselors and laboratory technicians for second-line antiretroviral therapy drugs, operational guidelines for pilot roll-out in two centres and laboratory guidelines for viral-load testing and standard operating procedure...
It's time to deliver differently.
Accessed: 13.11.2019
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
Vol. 2: Clinicians' Guide
Clinicians’ Guide is designed to assist busy medical practitioners in the field with patient management by providing current, essential, practical guidance and background, packaged into a single resource
Clinicians’ Guide is designed to assist busy medical practitioners in the field with patient management by providing current, essential, practical guidance and background, packaged into a single resource
Guidelines for treatment of drug-susceptible tuberculosis and patient care
Update 2017
NOVEMBER 2012
This document serves as an update to “Out of the Dark”, a report published by MSF in October 2011, highlighting the need to prioritise the long-neglected area of paediatric tuberculosis (TB). This update will outline the key improvements and setbacks—the ‘highlights’ and ‘...
NATIONAL TUBERCULOSIS AND LEPROSY PROGRAMME
Nepal: NTP General Manual, Nepali version
recommended
National Guidelines for Antiretroviral Therapy
recommended
“Continuum of HIV services refers to a comprehensive package of HIV prevention, diagnostic, treatment, care and support services provided for people at risk of HIV infection or living with HIV and their families”
August, 2018
Tuberculosis (TB) is among the top ten most common causes of death globally and as a single infectious disease it top among infectious diseases. Furthermore, it is noted as the top causes of death among people infected with the human immunodeficiency virus (HIV). Despite recent decreases in the numb...
Geneva, Switzerland 9th March 2016
PHARMA’S RESPONSE TO THE COVID-19 VACCINES CRISIS. Update Feb., 14, 2022. In September 2021, Amnesty International published A Double Dose of Inequality, which assessed the extent to which the pharmaceutical industry was restricting access to Covid-19 vaccines. This report updates that assessment ...
Mission report April 2016
